Journal
RSC ADVANCES
Volume 12, Issue 35, Pages 22448-22457Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2ra00486k
Keywords
-
Categories
Ask authors/readers for more resources
In this study, researchers utilized drug databases and virtual screening analysis to identify a promising candidate drug, remdesivir, against SARS-CoV-2. They also designed analogs HA-130383 and HA-130384 based on scaffold replacement and structure-based pharmacophore. These analogs showed potential as lead compounds.
By the end of 2019, a novel strain of the corona viral family named SARS-CoV-2 emerged in Wuhan, China and started to spread worldwide causing one of the most dangerous lethal pandemics. Researchers utilized various reported inhibitors and drug databases for virtual screening analysis against this novel strain. Later on, they succeeded to fish and repurpose remdesivir, an antiviral nucleotide analogue that inhibits RNA polymerase of the Ebola virus, as a promising candidate against SARS-CoV-2. In this study, we used the interactions of the co-crystallized metabolite of remdesivir with SARS-CoV-2 RdRp isozyme (PDB 7BV2) to design an analog with potential extra activity. This design was based on a scaffold replacement of a pyrrolotriazine moiety. This design was guided by a generated structure-based pharmacophore. The database generated from scaffold replacement was subjected to molecular docking and molecular dynamics simulations within the active site of SARS-CoV-2 RdRp (PDB 7BV2) to suggest HA-130383 and HA-130384 as potential lead compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available